Véronique Dieras

Head Breast Group

France

Research Interests

Explore related searches

Professors in France Professors in Cancer Biology Cancer Biology professors in France

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Véronique Dieras is the Head of the Breast Group at the Centre Eugène Marquis in France. Her research focuses on metastatic triple-negative breast cancer and hormone receptor positive breast cancer, with notable contributions to the ASCENT study and various safety analyses. Recent publications discuss treatment efficacy and prognostic factors in advanced breast cancer, emphasizing the complexities surrounding therapeutic options and patient outcomes.

Articles (9)

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Collaborators (4)

Lisa Anne Carey

University of North Carolina at Chapel Hill

UNITED STATES

View details

Seock-Ah Im

Professor

Seoul National University College of Medicine

SOUTH KOREA

View details

Kevin Kalinsky

Emory University

UNITED STATES

View details

Anthony Gonçalves

Aix-Marseille University

FRANCE

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Véronique Dieras

Research Interests

Explore related searches

Contact this professor

About

Articles (9)

The association of high body mass index with the safety and efficacy of sacituzumab govitecan in patients with metastatic triple-negative breast cancer from the ASCENT study

Overall Survival With Palbociclib Plus Letrozole in Advanced Breast Cancer

Author Correction: Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer

Subgroup analyses from the phase 3 ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer

Long-Term Results with Everolimus in Advanced Hormone Receptor Positive Breast Cancer in a Multicenter National Real-World Observational Study

Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer

Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer—phase 3 ASCENT study subanalysis

De novo metastatic breast cancer in patients with a small locoregional tumour (T1-T2/N0): Characteristics and prognosis

Relevance of Platinum-free Interval and BRCA Reversion Mutations for Veliparib Monotherapy after Progression on Carboplatin/Paclitaxel for gBRCA Advanced Breast Cancer (BROCADE3 Crossover)

Collaborators (4)

Lisa Anne Carey

Seock-Ah Im

Kevin Kalinsky

Anthony Gonçalves

Make your next move.